Profound Medical Corp

Research Profound Medical Corp (PROF) on Bullrun: market cap USD 248.79M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 248.79M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 16.10M-USD 42.57M-USD 38.38M70.8%1.41USD 59.72MUSD 4.50MUSD 66.43M
FY2024USD 9.74M-USD 27.82M-USD 23.22M72.2%1.12USD 54.91MUSD 4.66MUSD 60.42M
FY2023USD 5.90M-USD 28.32Mn/a73.1%1.34USD 26.21MUSD 7.10MUSD 31.22M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 248.79Mn/an/an/a
20252025-12-31USD 285.63Mn/an/an/a
20242024-12-31USD 225.60Mn/an/an/a
20232023-12-29USD 181.39Mn/an/an/a
20222022-12-30USD 227.34Mn/an/an/a
20212021-12-31USD 233.32Mn/an/an/a

About Profound Medical Corp

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Profound Medical Corp's market cap?

Profound Medical Corp's market capitalization is USD 248.79M.

What does Profound Medical Corp do?

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.